DFFN - Diffusion Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.0000
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.0000
Open2.9447
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range2.9447 - 3.1300
52 Week Range1.8300 - 11.0000
Volume78,599
Avg. Volume336,220
Market Cap14.089M
Beta (3Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-5.2630
Earnings DateMar 27, 2019 - Apr 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • GlobeNewswire23 days ago

    Diffusion Pharmaceuticals Inc. Announces Closing of $6.45 Million Offering Priced At-the-Market

    Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously announced registered direct offering, priced at-the-market, with certain institutional investors of 1,317,060 shares of the Company’s common stock, at a price of $4.77 per share, for aggregate gross proceeds of approximately $6.28 million. The Company also issued 1,317,060 unregistered warrants to the institutional investors in a concurrent private placement to purchase one share of common stock for each share of common stock purchased with an exercise price of $5.00 per share for aggregate gross proceeds of approximately $165 thousand.

  • GlobeNewswire27 days ago

    Diffusion Pharmaceuticals Inc. Announces $6.45 Million Registered Direct Offering & Private Placement

    Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced that it has entered into a definitive securities purchase agreement with certain institutional investors to purchase in a registered direct offering 1,317,060 shares of the Company’s common stock, at a price of $4.77 per share, for aggregate gross proceeds of approximately $6.28 million. The Company also agreed to issue 1,317,060 unregistered warrants to the institutional investors in a concurrent private placement to purchase one share of common stock for each share of common stock purchased with an exercise price of $5.00 per share for aggregate gross proceeds of approximately $165 thousand.

  • GlobeNewswire28 days ago

    Diffusion Pharmaceuticals Receives Notice of Intention to Grant a Patent Related to Use of TSC in Combination with tPA in Ischemic Stroke from European Patent Office

    Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced receipt from the European Patent Office of a Notice of Intention to Grant a patent related to the use of the Company’s lead compound trans sodium crocetinate (“TSC”) in combination with the leading thrombolytic, tissue plasminogen activator (“tPA”), in the treatment of ischemic stroke. The patent claim covers administration of TSC within three or four hours of the onset of stroke symptoms in combination with tPA administered within nine to 12 hours of the onset of stroke symptoms.

  • Zacks Small Cap Researchlast month

    DFFN: Phase 2 Study of TSC in Stroke to Start in Summer 2019…

    Diffusion Pharmaceuticals, Inc. (DFFN) is currently planning to conduct the Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T), which will be a randomized, double blind, placebo controlled Phase 2 trial with an anticipated enrollment of 160 ambulance-transported patients (80 active/80 placebo) treated within two hours of the onset of a suspected stroke. In addition, patients are eligible to receive tPA separately in-hospital if it is determined they are suffering from an ischemic stroke. In October 2018, Diffusion received approval from the U.S. FDA to enroll patients in the study.

  • GlobeNewswirelast month

    Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

    CHARLOTTESVILLE, Va., May 09, 2019 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical.

  • Zacks Small Cap Research2 months ago

    DFFN: Data from Initial 8 Patients in Phase 3 GBM Trial Expected in mid-2019…

    Diffusion Pharmaceuticals, Inc. (DFFN) is currently conducting the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial. The trial is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis. Following a dose-escalation run-in period, in which eight patients will receive ascending doses of TSC along with temozolimid (TMZ) for two 28-day cycles, patients will be randomized 1:1 to receive TSC along with standard of care radiation therapy (RT) and chemotherapy (TMZ) or standard of care alone.

  • GlobeNewswire3 months ago

    Diffusion Pharmaceuticals Reports 2018 Financial Results and Provides Business Update

    CHARLOTTESVILLE, Va., March 20, 2019 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening.

  • 4 Stocks Join Ben Graham Net-Net Screener Friday
    GuruFocus.com3 months ago

    4 Stocks Join Ben Graham Net-Net Screener Friday

    While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been active

  • GlobeNewswire4 months ago

    Poster Presented at International Stroke Conference Describing Diffusion’s On-Ambulance Phase 2 Trial with TSC for Treating Acute Stroke

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced the presentation of a poster detailing an innovative on-ambulance Phase 2 study with the Company’s lead drug trans sodium crocetinate (TSC) for the treatment of acute stroke. The poster was presented on February 7th at the American Heart Association’s International Stroke Conference, held February 6-8 in Honolulu.

  • How Does Investing In Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Impact The Volatility Of Your Portfolio?
    Simply Wall St.5 months ago

    How Does Investing In Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Impact The Volatility Of Your Portfolio?

    If you own shares in Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • GlobeNewswire5 months ago

    Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that Chief Executive Officer David Kalergis will join investors, executives, civic leaders, and scientists to present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 7:00pm EST/4:00pm PST. The Conference will be held on January 7-10, 2019 at the Westin St. Francis Hotel in San Francisco, California.

  • GlobeNewswire6 months ago

    Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced it received notice from NASDAQ staff that the Company has regained compliance with Listing Rule 5550(a)(2) and will remain listed on the NASDAQ stock market. The news came as a result of the closing bid price of Diffusion’s stock remaining above $1.00 per share between December 14 and December 28, 2018. This latest news follows a number of exciting recent developments, including FDA approval of a Phase 2 on-ambulance clinical trial for the treatment of stroke using the Company’s lead drug, Trans Sodium Crocetinate (TSC) and the U.S. Patent Office awarding the Company a patent for the use of TSC in conjunction with Tissue Plasminogen Activator (tPA), which remains the only FDA-approved therapeutic stroke treatment.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Evofem Biosciences had a day of gains on Monday after announcing positive results on its hormone free birth control gel. Shares of Diffusion Pharmaceuticals were in the red despite announcing that the company was awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke.

  • ACCESSWIRE6 months ago

    4 Stocks Providing Investor Opportunity Right Now

    On Monday 12/17/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Diffusion Pharmaceuticals Inc. (DFFN), Evofem Biosciences, Inc. (EVFM) and Synergy Pharmaceuticals Inc. (SGYP) are presenting investors with upside opportunity ahead of Christmas and the 2019 New Year. Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) a company you may have not heard of yet, has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.

  • GlobeNewswire6 months ago

    U.S. Patent Office Awards Diffusion Exclusive Rights for Use of TSC in Conjunction with Only FDA-Approved Stroke Therapeutic

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that it has been awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke. Currently, tPA – a thrombolytic used to break down blood clots in patients suffering from ischemic stroke – is the only FDA-approved therapeutic stroke treatment.

  • GlobeNewswire6 months ago

    Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-15, effective for trading purposes prior to the opening of the market on December 14, 2018. The Company’s ticker symbol, DFFN, will remain unchanged. The new CUSIP number for Diffusion’s post-reverse split common stock will be 253748 305.

  • Zacks Small Cap Research6 months ago

    DFFN: Phase 2 Clinical Trial of TSC in Acute Stroke to Commence in 2019…

    In early 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” to be presented at the International Stroke Conference. The abstract discussed the design and rationale for a planned Phase 2 study of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation, in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. The Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T) will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke.

  • GlobeNewswire7 months ago

    Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology

    Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that Chief Scientific Officer Dr. John L. Gainer will join leading clinicians and researchers from around the world in presenting a poster at the 2018 Annual Meeting of the Society for NeuroOncology (SNO) on Saturday, November 17, 2018 from 5:00-7:00pm EST. SNO’s 23rd Annual Scientific Meeting and Education Day will be held from Thursday, November 15, 8:00am through Sunday, November 18, 1:00pm at the Marriott Hotel, New Orleans, Louisiana.

  • GlobeNewswire7 months ago

    Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Officer CHARLOTTESVILLE, Va., Nov. 14,.

  • Zacks Small Cap Research10 months ago

    DFFN: Enrollment Continues in Phase 3 Trial of TSC in GBM

    Early in 2018, Diffusion (DFFN) announced that the first patient has been dosed in the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial. The trial is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis. Patients will be randomized 1:1 to receive TSC along with standard of care radiation and chemotherapy (temozolimide) or standard of care alone.